利法西明-阿尔法增加乳糖酶活性在患有刺激性肠综合征的患者没有便秘和小肠细菌过度生长
María Fernanda García-Cedillo1,2, Federico Ulises Villegas-García3, Josealberto Sebastiano Arenas-Martinez2
1Programa de Maestría y Doctorado en Ciencias Médicas, Odontológicas y de la Salud, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Digestive diseases and sciences
|December 6, 2024
概括
利法西明-阿尔法改善了患者的刺激性肠综合征症状,并减少了乳糖消化不良. 治疗还减少了小肠细菌过度生长 (SIBO) 的阳性呼吸测试.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 刺激性肠综合征 (IBS) 的症状与小肠细菌过度生长 (SIBO) 和食物不耐受有关,影响了乳糖等消化酶的活性.
- SIBO可以降低乳糖酶活性,从而导致IBS患者的乳糖不耐症症状.
研究的目的:
- 评估rifaximin-alpha在缓解IBS症状方面的有效性.
- 评估rifaximin-alpha对没有便秘的IBS患者乳糖酶活性和SIBO的影响.
主要方法:
- 一项前性试点研究涉及IBS患者 (罗马IV标准) 确诊SIBO和乳糖不耐受.
- 患者接受了rifaximin-alpha (400毫克每8小时两周).
- 在治疗前和治疗后进行了症状评估,D-Xylose水平和乳糖和SIBO的气呼吸测试 (HBT).
主要成果:
- 报告有显著的症状改善:腹部疼痛 (60%),胀气 (44%),气胀 (36%),borborygmi (60%) 和便的一致性 (72%).
- SIBO的患病率下降,32%的患者在治疗后检测出阴性.
- 根据乳糖HBT结果,乳糖消化不良从88%降至52%.
结论:
- 利法西明-阿尔法在没有便秘的患者中有效改善了IBS症状.
- 治疗减少了乳糖消化不良和积极的SIBO呼吸测试结果.
- 利法西明-α在治疗与SIBO和乳糖不耐症相关的IBS方面表现出潜在的潜力.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
316
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
316
Irritable Bowel Syndrome III: Medical and Nursing Management
167
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
167
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Irritable Bowel Syndrome I: Introduction
246
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
246


